The aim of the present study was to evaluate the effects of increased expression of the oncogene CDH13 following exposure to saRNAs and to explore the effects of CDH13 on BCR-ABL1-independent resistant CML cells and the related mechanisms to identify a new feasible approach to overcome resistant in CML treatment. Here, CDH13 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.